Milestone Pharmaceuticals Inc (NAS:MIST)

Q1 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript

May 13, 2026 / 12:30 PM GMT

Release Date Price: $1.72 (-9.47%)

Transcript 8-K10-Q

Key Points

Positve

Successful commercial launch of Cardamis for acute PSVT, with positive reception from healthcare providers and patients.
Express Scripts National Formulary Coverage achieved, providing access to approximately 25% of commercially insured patients.
Initiation of Phase III trial for atripamil in AFib-RVR, building on successful Phase II results.
Strong financial position with $184 million in cash and equivalents, providing runway into the second half of 2027.
Steady month-over-month growth in prescriptions, with 600 total prescriptions by the end of April.

Negative

Net loss of $26.1 million for Q1 2026, an increase from $20.8 million in Q1 2025.
Product revenues were only $0.2 million in the first quarter, indicating early-stage challenges in revenue generation.
High commercial expenses of $15.8 million due to launch activities, impacting overall financial performance.
Limited coverage beyond Express Scripts, with ongoing negotiations needed to expand payer access.
Initial prescription volume is still low, with only 400 unique healthcare professionals writing prescriptions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MIST.OQ - Milestone Pharmaceuticals Inc
Q1 2026 Milestone Pharmaceuticals Inc Earnings Call
May 13, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good morning and welcome to the Milestone Pharma First Quarter 2026 Earnings Conference Call.

At this time, all participants are in listen-only mode.

A brief question-and-answer session will follow the formal presentation.

If anyone requires operator assistance during the conference, please signal the operator by pressing and 0 on your telephone keypad.

As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Michael Wood of LifeSci Advisor. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.